/TARS
TARS Stock - Tarsus Pharmaceuticals, Inc.
Healthcare|BiotechnologyNASDAQ
$81.40+5.06%
+$3.92 (+5.06%) • Dec 19
73
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.97
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).58
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.90
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+4.1%upside
Target: $84.74
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for TARS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$80.59 – $82.21
TARGET (TP)$84.75
STOP LOSS$74.89
RISK/REWARD1:0.5
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.75
52W High$85.25
52W Low$38.51
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $182.95M | $17.45M | $25.82M | $57.03M | N/A |
| Gross Profit | $170.13M | $15.85M | $24.86M | $54.95M | $-246,000 |
| Gross Margin | 93.0% | 90.9% | 96.3% | 96.4% | N/A |
| Operating Income | $-120,569,000 | $-143,158,000 | $-62,712,000 | $-12,157,000 | $-26,983,000 |
| Net Income | $-115,554,000 | $-135,893,000 | $-62,091,000 | $-13,827,000 | $-26,811,000 |
| Net Margin | -63.2% | -778.9% | -240.5% | -24.2% | N/A |
| EPS | $-3.07 | $-4.62 | $-2.52 | $-0.67 | $-1.32 |
Company Overview
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
5
83%
Hold / Neutral
1
17%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
5 Bullish1 Neutral/Bearish
Price Targets
$64
Average Target
↓ 21.0% Downside
Now
$19
Low
$64
Average
$100
High
Based on 7 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 9th 2025 | Barclays | Initiation | Overweight | $100 |
| November 20th 2025 | Mizuho | Initiation | Outperform | $100 |
| June 2nd 2025 | Oppenheimer | Resumed | Outperform | $75 |
| May 27th 2025 | H.C. Wainwright | Resumed | Buy | $72 |
| November 20th 2023 | Goldman | Initiation | Neutral | $19 |
| July 18th 2023 | William Blair | Initiation | Outperform | $44 |
| May 18th 2023 | Guggenheim | Initiation | Buy | - |
| August 1st 2022 | Barclays | Initiation | Overweight | $40 |
Earnings History & Surprises
TARSBeat Rate
78%
Last 18 quarters
Avg Surprise
+18.3%
EPS vs Estimate
Beats / Misses
14/4
Last 12 quarters
Latest EPS
$-0.30
Q4 2025
EPS Surprise History
Q1 24
+4.4%
$-1.31vs$-1.37
Q2 24
+12.2%
$-1.01vs$-1.15
Q3 24
+10.2%
$-0.88vs$-0.98
Q4 24
+35.1%
$-0.61vs$-0.94
Q1 25
+11.8%
$-0.60vs$-0.68
Q2 25
+7.2%
$-0.64vs$-0.69
Q3 25
-45.5%
$-0.48vs$-0.33
Q4 25
+14.3%
$-0.30vs$-0.35
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 29, 2026 | — | — | — | — |
Q1 2026 | Feb 24, 2026 | $-0.16 | — | — | — |
Q4 2025 | Nov 4, 2025 | $-0.35 | $-0.30 | +14.3% | ✓ BEAT |
Q3 2025 | Aug 6, 2025 | $-0.33 | $-0.48 | -45.5% | ✗ MISS |
Q2 2025 | May 1, 2025 | $-0.69 | $-0.64 | +7.2% | ✓ BEAT |
Q1 2025 | Feb 25, 2025 | $-0.68 | $-0.60 | +11.8% | ✓ BEAT |
Q4 2024 | Nov 13, 2024 | $-0.94 | $-0.61 | +35.1% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.98 | $-0.88 | +10.2% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $-1.15 | $-1.01 | +12.2% | ✓ BEAT |
Q1 2024 | Feb 27, 2024 | $-1.37 | $-1.31 | +4.4% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-1.40 | $-1.28 | +8.6% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-1.08 | $-1.17 | -8.3% | ✗ MISS |
Q2 2023 | May 9, 2023 | $-0.95 | $-0.88 | +7.4% | ✓ BEAT |
Q1 2023 | Mar 13, 2023 | $-0.97 | $-0.49 | +49.5% | ✓ BEAT |
Q4 2022 | Nov 9, 2022 | $-0.98 | $-0.84 | +14.3% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-0.65 | $-0.24 | +63.1% | ✓ BEAT |
Q2 2022 | May 10, 2022 | $-0.87 | $-0.98 | -12.6% | ✗ MISS |
Q1 2022 | Mar 14, 2022 | $-0.77 | $-0.72 | +6.5% | ✓ BEAT |
Q4 2021 | Nov 9, 2021 | $-0.65 | $-0.76 | -16.9% | ✗ MISS |
Q3 2021 | Aug 4, 2021 | $-0.48 | $0.33 | +168.8% | ✓ BEAT |
Latest News
Barclays Initiates Coverage On Tarsus Pharmaceuticals with Overweight Rating, Announces Price Target of $100
📈 PositiveBenzinga•Dec 9, 2025, 04:19 PM•Also:
Mizuho Initiates Coverage On Tarsus Pharmaceuticals with Outperform Rating, Announces Price Target of $100
📈 PositiveBenzinga•Nov 20, 2025, 04:10 PM
Guggenheim Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $87
📈 PositiveBenzinga•Nov 5, 2025, 03:04 PM
Tarsus Pharmaceuticals shares are trading lower. The company reported Q3 financial results.
📉 NegativeBenzinga•Nov 4, 2025, 10:10 PM
Tarsus Pharmaceuticals Q3 EPS $(0.30) Beats $(0.38) Estimate, Sales $118.697M Beat $115.222M Estimate
📈 PositiveBenzinga•Nov 4, 2025, 09:06 PM
HC Wainwright & Co. Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $88
📈 PositiveBenzinga•Oct 20, 2025, 10:40 AM
Frequently Asked Questions about TARS
What is TARS's current stock price?
Tarsus Pharmaceuticals, Inc. (TARS) is currently trading at $81.40 per share. The stock has moved +5.06% today.
What is the analyst price target for TARS?
The average analyst price target for TARS is $84.75, based on 1 analyst.
What sector is Tarsus Pharmaceuticals, Inc. in?
Tarsus Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is TARS's market cap?
Tarsus Pharmaceuticals, Inc. has a market capitalization of $3.46 billion, making it a mid-cap company.
Does TARS pay dividends?
No, Tarsus Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAAPG
ASCENTAGE PHARMA GROUP INTERNATIONAL
$29.31
Mkt Cap: $2.7B
ADPT
Adaptive Biotechnologies Corporation
$17.00
Mkt Cap: $2.6B
ARQT
Arcutis Biotherapeutics, Inc.
$28.01
Mkt Cap: $3.4B
CELC
Celcuity Inc.
$101.16
Mkt Cap: $4.7B
CGON
CG Oncology, Inc. Common stock
$39.03
Mkt Cap: $2.9B
IRON
Disc Medicine, Inc.
$80.04
Mkt Cap: $3.0B
LEGN
Legend Biotech Corporation
$21.92
Mkt Cap: $2.0B
SRRK
Scholar Rock Holding Corporation
$43.90
Mkt Cap: $4.5B
TVTX
Travere Therapeutics, Inc.
$34.51
Mkt Cap: $3.1B
ZLAB
Zai Lab Limited
$18.04
Mkt Cap: $2.0B
Explore stocks similar to TARS for comparison